All three sites of LAB Research have now received OECD-GLP compliance status
Toronto Stock Exchange Symbol: LRI
LAVAL, QC, June 2 /CNW Telbec/ - LAB Research Inc. ("LAB" or "LAB Research"), (TSX: LRI), a Canadian-based global non-clinical contract research organization ("CRO"), today announced that its Canadian laboratory has received a Good Laboratory Practices ("GLP") recognition from the Standards Council of Canada ("SCC").
GLP compliance of the site has been recognized by formal document issued in May 2010 under the Standards Council of Canada GLP Compliance Program based upon an inspection and study audits conducted in November 2009 in the area(s) of Analytical and Clinical Chemistry, ADME, Bioanalytical, Immunology, Safety Pharmacology, Toxicokinetics and Toxicity testing of Pharmaceuticals.
"The confirmation of our GLP compliance status reaffirms the Canadian site's GLP compliance to OECD-GLP standards following the successful audit by the German authorities several years ago," commented Luc Mainville, President and Chief Executive Officer of LAB Research.
"This successful OECD-GLP Inspection of our Canadian laboratory also follows successful GLP audits of each of our Danish and Hungarian laboratories. We are pleased to offer the greatest level of quality and GLP compliant environment to our clients around the world. These positive GLP audits will help us broaden our clientele following our service and site expansions that positioned LRI as a high quality, global full service non-clinical CRO," added Luc Mainville.
About the Standards Council of Canada:
The Standards Council of Canada (SCC) is a federal Crown corporation. It has its mandate to promote efficient and effective standardization in Canada. Located in Ottawa, the Standards Council has a 15-member governing Council and a staff of approximately 90. The organization reports to Parliament through the Minister of Industry and oversees Canada's National Standards System.
About LAB Research Inc.:
LAB Research is a Canadian global non-clinical contract research organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petro-chemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in Canada, Denmark and Hungary.
LAB Research's shares trade on the TSX under the symbol "LRI", with 52.7 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB Research Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
SOURCE LAB RESEARCH INC.
For further information: For further information: Luc Mainville, Chief Executive Officer, (450) 973-2240 (ext. 1206), email@example.com; Frédéric Dumais, Partner, Jasmin-Dumais Financial Communications, (514) 862-1251, firstname.lastname@example.org; www.labresearch.com